MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Michigan
Esperion Therapeutics, Inc. (NASDAQ: ESPR)*
Organization & Developments: Esperion
Parents
Esperion Therapeutics, Inc. (NASDAQ: ESPR)*
Children
*Biopharmaceutical company focused on developing and commercializing non-statin, complementary, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).
*Dr. Newton co-discovered the statin marketed as Lipitor, which is the most commonly prescribed LDL-C lowering therapy and is the best-selling drug in the history of the pharmaceutical industry.
*Dr. Newton oversaw the transfer of ownership when Esperion was originally acquired in 2004 by Pfizer (NYSE: PFE) and oversaw Esperion going independent from Pfizer in 2008 when he raised the capital to acquire the rights to ETC-1002.
*The company’s lead product candidate is bempedoic acid which is a treatment for patients with elevated LDL-C who are not adequately treated with current lipid-modifying therapies.
2018: Esperion Strikes Home Run On First Study For Cholesterol Drug_seekingalpha.com
2019: Esperion Is The One To Watch, After FDA Deems Advisory Panel Is Not Needed_seekingalpha.com
2019: Esperion Therapeutics: Low Risk And Primed For Substantial Growth_seekingalpha.com
2019: The Verdict On Esperion Therapeutics_seekingalpha.com
2020: Esperion Therapeutics: Major Potential In Bempedoic Acid/Ezetimibe Combination For LDL-C Lowering_seekingalpha.com
2020: Esperion Wins FDA Approval for its Oral, Cholesterol-Lowering Drug
2020: Esperion: Analysis Of Prospects And Latest Earnings Call
2020: Esperion: Early Commercial Success Supports A Buy At These Prices
2020: The Play On Esperion Therapeutics
2021: Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection
2021: Esperion: Interesting Case
2022: Esperion Therapeutics: Q3 Earnings Reveal Progress Ahead Of CLEAR Outcomes Data_ seekingalpha.com
2022: Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout_seekingalpha.com
2023: Esperion Therapeutics: A Speculative Buy Amidst Extreme Pessimism_ seekingalpha.com
2024: Esperion Is Sitting On A Potential Blockbuster Drug_ seekingalpha.com
2024: Esperion Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2025: Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Jumps
*Key People: Esperion
Finance & Acquisitions: Esperion